At the news
? NEUTRALIMPACT 4/10 8-K filed May 12, 2026 at 06:30 ET
Zimmer Biomet announced an increased share repurchase expectation for FY2026, now targeting up to $1.0 billion in buybacks under its existing $1.5 billion authorization. This represents a $250 million increase from prior capital allocation assumptions, signaling management's confidence in cash flow and commitment to returning capital.
- Company intends to repurchase up to $1.0 billion of shares in FY2026
- Increase of $250 million from prior capital allocation assumption
- Repurchases under existing $1.5 billion authorization approved in February 2026
- No changes to the size, duration or terms of the authorization
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access